Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer

Endocrine Journal

Volumn 54, Issue 3, 2007, Pages 399-405

  Kumagai, Atsushi ^a,b   Namba, Hiroyuki ^a   Akanov, Zhanay ^a   Saenko, Vladimir A ^a   Meirmanov, Serik ^a   Ohtsuru, Akira ^c   Yano, Hiroshi ^a   Maeda, Shigeto ^a   Anami, Masanobu ^c   Hayashi, Tomayoshi ^c   Ito, Masahiro ^d   Sagandikova, Sagadat ^e   Eleubaeva, Zhanar ^f   Mussinov, Daniyal ^f,g   Espenbetova, Maira ^g   Yamashita, Shunichi ^a,b,c  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^e Semipalatinsk Diagnostic Center   (Kazakhstan)

^f Semipalatinsk Regional Oncology Center   (Kazakhstan)

^g SEMEY MEDICAL UNIVERSITY   (Kazakhstan)

Author keywords

BRAF; Fine needle aspiration biopsy; Mutation; Papillary thyroid carcinoma

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER DIAGNOSIS; CLINICAL PRACTICE; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; JAPANESE; KAZAKHSTAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; NUCLEAR INDUSTRY; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; CHILD; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; JAPAN; KAZAKHSTAN; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREOPERATIVE CARE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 34547101485     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-194     Document Type: Article

References (28)

1. Vander JB, Gaston EA, Dawber TR (1968) The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 69: 537-540.
2. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA (1977) The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 7: 481-493.
3. Tan GH, Gharib H (1997) Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126: 226-231.
4. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassillopoulou-Sellin R, Lee JE, Evans DB (2003) Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 186: 702-709; discussion 709-710.
5. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373-6379.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
7. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22: 6455-6457.
8. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627.
9. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397.
10. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404.
11. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580.
12. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567.
13. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D (2004) BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89: 1365-1368.
14. T1796A mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14: 910-915.
15. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M (2004) Analysis of BRAF point mutation and RET/PTC rearrangement refines the fineneedle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89: 5175-5180.
16. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW (2004) Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89: 2867-2872.
17. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45: 818-821.
18. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90: 5265-5269.
19. Hedinger C, Williams ED, Sobin LH (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63: 908-911.
20. V600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation. Endocrinology 147: 5699-5707.
21. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473.
22. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245.
23. V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13: 257-269.
24. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10: 6821-6829.
25. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629.
26. T1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4280-4284.
27. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4267-4271.
28. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209: 1-6.